%0 Journal Article
%T Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.
%A Paireau J
%A Durand C
%A Raimbault S
%A Cazaubon J
%A Mortamet G
%A Viriot D
%A Milesi C
%A Daudens-Vaysse E
%A Ploin D
%A Tessier S
%A Vanel N
%A Chappert JL
%A Levieux K
%A Ollivier R
%A Daoudi J
%A Coignard B
%A Leteurtre S
%A Parent-du-Châtelet I
%A Vaux S
%J Influenza Other Respir Viruses
%V 18
%N 6
%D 2024 Jun
%M 38840301
%F 5.606
%R 10.1111/irv.13311
%X In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.